Cholesterol management is not simply about blocking a single enzyme (as statins do). Optimal lipid balance involves hepatic cholesterol synthesis and clearance, lipoprotein structure and particle size, triglyceride metabolism, inflammation, insulin sensitivity, and body composition — all of which are influenced by peptide signaling.
Growth hormone optimization via secretagogue peptides (CJC-1295, Ipamorelin) has well-documented effects on lipid profiles: GH lowers LDL, raises HDL, and reduces visceral fat — all favorable cardiovascular outcomes. AOD-9604, a fragment of HGH, specifically targets fat metabolism and has shown lipid-improving effects.
BPC-157 has demonstrated hepatoprotective effects in research — protecting the liver from damage and supporting optimal hepatic function, which is central to cholesterol processing. Optimizing growth hormone consistently improves the LDL/HDL ratio in clinical studies.
At Body Symmetry MD, we assess your complete cardiovascular risk picture — including LDL particle number, ApoB, hs-CRP, insulin resistance markers, and body composition — before designing a peptide protocol to address your specific lipid issues at the root level.